The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2023Preclinical Development of Disease-modifying Therapies for Treating Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by the hallmark accumulation of toxic clumps of alpha-synuclein, particularly a modified form of the protein called pS129. Acurex has...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Examining the Role of LRRK2 and Glucocerebrosidase Dysfunction in Exosome-mediated Release of the Lipid Biomarker Bis(monocylglycero)phosphate in Parkinson's Disease
Study Rationale: Mutations in LRRK2 and GBA1 (which encodes the enzyme glucocerebrosidase, or GCase) are among the most common genetic risk factors for Parkinson’s disease (PD). Individuals with these...
-
ASAP, 2023(SUPPLEMENT) Examining How Genes and Gut Bacteria Cooperate to Cause Parkinson’s Disease
Study Rationale: Recent studies suggest that the alpha-synuclein protein that forms aggregates in Parkinson’s disease (PD) may originate in the gut and travel along nerves that go to the brain...
-
ASAP, 2023(SUPPLEMENT) Using Single-cell Analyses to Understand Inherited and Acquired Genetic Variation in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a disorder that not only affects the function of the brain, but also the gut. Both of these are complex tissues composed of functionally diverse cell types...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
-
Lysosomal Biomarkers Program, 2023Investigating the Role of Lysosomal Biomarker ATP13A2 in the Pathogenesis of Parkinson’s Disease
Study Rationale: Lysosomal impairment is strongly implicated in the pathology of Parkinson’s disease (PD). Loss-of-function mutations in ATP13A2, a gene that encodes a lysosomal protein, are causally...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.